Recital 4, Directive (EU) 2012/52

In forcesince 20 Dec 2012

Medicinal products should therefore be indicated using the common name in order to facilitate the correct identification of products which are marketed under different brand names across the Union and of products that are not marketed in all Member States. That common name to be used should be either the International Non-proprietary name recommended by the World Health Organisation or, if such name does not exist, the usual common name. In contrast, the brand name of a medicinal product should only be used to ensure clear identification of biological medicinal products as defined in point 3.2.1.1.(b) of Annex I to Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community Code relating to medicinal products for human use [OJ L 311, 28.11.2001, p. 67.], because of the special characteristics of those products, or of other medicinal products in cases where the prescribing professional considers it medically necessary.